A multi-site, randomized, double-blind, multi-arm historical control, comparative trial of the safety and efficacy of hydroxychloroquine and the combination of hydroxychloroquine and famotidine for…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50120C00078
- Awardee
-
Alchem Laboratories Corporation UEI LD2KY6H7KMQ5
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $4,668,079
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Multi-site, randomized, double-blind, multi-arm historical control, comparative trial of the safety and efficacy of hydroxychloroquine and the combination of hydroxychloroquine and famotidine for treatment of moderate to severe COVID-19 disease in hospital Award Notice · Posted Apr 22, 2020
- Contract value 100% obligated
- $4,668,079.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Santa Fe, FL 32615, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$16,078,939 | |
| Other Administrative Action | $0 | |
| Original award | $20,747,018 |
About this award
This is a $4,668,079 firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Alchem Laboratories Corporation, a for-profit pharmaceutical manufacturer, for a multi-site, randomized, double-blind, comparative clinical trial evaluating the safety and efficacy of hydroxychloroquine and the combination of hydroxychloroquine and famotidine for the treatment of moderate to severe COVID-19 disease. The contract has an ultimate completion date of August 5, 2024. This contract award is not associated with a set-aside designation. Alchem Laboratories Corporation has previously received prime federal contracts and grants from agencies like the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and Defense Threat Reduction Agency for pharmaceutical development and manufacturing services.
Description
A multi-site, randomized, double-blind, multi-arm historical control, comparative trial of the safety and efficacy of hydroxychloroquine and the combination of hydroxychloroquine and famotidine for the treatment of moderate to severe covid-19 disease
Quick answers
Who was awarded contract 75A50120C00078?
75A50120C00078 was awarded to Alchem Laboratories Corporation by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on April 14, 2020.
How much is contract 75A50120C00078 worth?
The government has obligated $4,668,079 on 75A50120C00078.
Was contract 75A50120C00078 competed?
The extent of competition for 75A50120C00078 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award